Nedaplatin: a cisplatin derivative in cancer chemotherapy

References

• KameyamaYOkazakiNNakagawaMKoshidaHNakamuraMGembaMNephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slicesToxicol Lett199052115242356567
   PubMed Web of Science ®Google Scholar
• NiiokaTUnoTYasui-FurukoriNPharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinomaCancer Chemother Pharmacol200759557558016912889
   PubMed Web of Science ®Google Scholar
• LebwohlDCanettaRClinical development of platinum complexes in cancer therapy: an historical perspective and an updateEur J Cancer19983410152215349893623
   PubMed Web of Science ®Google Scholar
• OtaKOgumaTShimamuraKPharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-SAnticancer Res1994143B138313878067710
   PubMed Web of Science ®Google Scholar
• SasakiYTamuraTEguchiKPharmacokinetics of (glycolate-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatinCancer Chemother Pharmacol19892342432462647312
   PubMed Web of Science ®Google Scholar
• OtaKWakuiAMajimaHPhase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)Gan To Kagaku Ryoho1992196:855861 Japanese1605663
   PubMedGoogle Scholar
• SasakiYAmanoTMoritaMPhase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusionCancer Res1991515147214771997185
   PubMed Web of Science ®Google Scholar
• UeharaTYamateJToriiMMaruyamaTComparative nephrotoxicity of cisplatin and nedaplatin: mechanisms and histopathological characteristicsJ Toxicol Pathol2011242879422272048
   PubMed Web of Science ®Google Scholar
• LieberthalWTriacaVLevineJMechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis versus necrosisAm J Physiol19962704F700F7088967349
   PubMed Web of Science ®Google Scholar
• CalvertAHNewellDRGumbrellLACarboplatin dosage: prospective evaluation of a simple formula based on renal functionJ Clin Oncol1989711174817562681557
   PubMed Web of Science ®Google Scholar
• ChatelutECanalPBrunnerVPrediction of carboplatin clearance from standard morphological and biological patient characteristicsJ Natl Cancer Inst19958785735807752255
   PubMedGoogle Scholar
• van WarmerdamLJRodenhuisSten Bokkel HuininkWWMaesRABeijnenJHThe use of the Calvert formula to determine the optimal carboplatin dosageJ Cancer Res Clin Oncol199512184784867642691
   PubMed Web of Science ®Google Scholar
• IshibashiTYanoYOgumaTA formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patientsCancer Chemother Pharmacol200250323023612203105
   PubMed Web of Science ®Google Scholar
• IshibashiTYanoYOgumaTPopulation pharmacokinetics of platinum after nedaplatin administration and model validation in adult patientsBr J Clin Pharmacol200356220521312895194
   PubMed Web of Science ®Google Scholar
• SatoSFujiwaraHOishiTEvaluation of a formula for individual dosage of nedaplatin based on renal functionCancer Chemother Pharmacol201269359960321918903
   PubMed Web of Science ®Google Scholar
• ShimadaMFujiwaraHSatoSArea under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignanciesCancer Chemother Pharmacol2012701333822610355
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
   PubMed Web of Science ®Google Scholar
• TeramotoKAsadaYOzakiYA phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancerCancer Chemother Pharmacol201270453153722864949
   PubMed Web of Science ®Google Scholar
• HiroseTSugiyamaTKusumotoSPhase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancerAnticancer Res20092951733173819443395
   PubMed Web of Science ®Google Scholar
• OshitaFYamadaKSaitoHNodaKHamanakaNIkeharaMPhase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancerJ Exp Ther Oncol20044434334815844664
   PubMedGoogle Scholar
• OshitaFYamadaKSaitoHNodaKPhase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancerCancer Chemother Pharmacol200862346547017960380
   PubMed Web of Science ®Google Scholar
• SugiyamaTHiroseTNakashimaMEvaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancerOncology2011813–427328022122886
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRvon PawelJEGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyLancet Oncol2012131334222056021
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• IlsonDHOesophageal cancer: new developments in systemic therapyCancer Treat Rev200329652553214585262
   PubMed Web of Science ®Google Scholar
• AjaniJAIlsonDHDaughertyKPazdurRLynchPMKelsenDPActivity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagusJ Natl Cancer Inst19948614108610917912736
   PubMedGoogle Scholar
• HeathEIUrbaSMarshallJPiantadosiSForastiereAAPhase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagusInvest New Drugs2002201959912003198
   PubMed Web of Science ®Google Scholar
• MuroKHamaguchiTOhtsuAA phase II study of single-agent docetaxel in patients with metastatic esophageal cancerAnn Oncol200415695595915151954
   PubMed Web of Science ®Google Scholar
• CaoWXuCLouGA phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancerJpn J Clin Oncol200939958258719509000
   PubMed Web of Science ®Google Scholar
• GongYRenLZhouLPhase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinomaCancer Chemother Pharmacol200964232733319048253
   PubMed Web of Science ®Google Scholar
• GuoJFZhangBWuFA phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinomaChin J Cancer201029332132420193118
   PubMedGoogle Scholar
• FujitaYHiramatsuMKawaiMSumiyoshiKNishimuraHTanigawaNEvaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective studyDis Esophagus200821649650118840134
   PubMed Web of Science ®Google Scholar
• JinguKMatsushitaHTakedaKLong-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II studyBMC Cancer20121254223171077
   PubMed Web of Science ®Google Scholar
• MonkBJSillMWMcMeekinDSPhase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group studyJ Clin Oncol200927284649465519720909
   PubMed Web of Science ®Google Scholar
• MonkBJAlbertsDSBurgerRAIn vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancersGynecol Oncol19987123083129826477
   PubMed Web of Science ®Google Scholar
• SasakiYShinkaiTEguchiKPrediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassayCancer Chemother Pharmacol19912742632701847845
   PubMed Web of Science ®Google Scholar
• KatoTNishimuraHYakushijiMPhase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancerGan To Kagaku Ryoho199219695701 Japanese1580643
   PubMedGoogle Scholar
• TakekumaMHirashimaYItoKPhase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group studyGynecol Oncol2012126334134522609108
   PubMed Web of Science ®Google Scholar
• YamaguchiSNishimuraRYaegashiNPhase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065)Oncol Rep201228248749322614251
   PubMed Web of Science ®Google Scholar
• TsudaHHashiguchiYNishimuraSPhase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancerBr J Cancer20049161032103715292935
   PubMed Web of Science ®Google Scholar
• NakamuraYHasegawaMHayakawaKInduction of p53-dependent apoptosis in vivo by nedaplatin and ionizing radiationOncol Rep20007226126510671668
   PubMed Web of Science ®Google Scholar
• TanakaTYukawaKUmesakiNRadiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitroEur J Gynaecol Oncol200728535235517966212
   PubMed Web of Science ®Google Scholar
• YokoyamaYTakanoTNakaharaKA phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit StudyOncol Rep20081961551155618497964
   PubMed Web of Science ®Google Scholar
• PignonJPle MaîtreAMaillardEBourhisJMACH-NC Collaborative GroupMeta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patientsRadiother Oncol200992141419446902
   PubMed Web of Science ®Google Scholar
• PignonJPBourhisJDomengeCDesignéLChemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck CancerLancet2000355920894995510768432
   PubMed Web of Science ®Google Scholar
• TakagiMSakataKSomeyaMGimeracil sensitizes cells to radiation via inhibition of homologous recombinationRadiother Oncol201096225926620584556
   PubMed Web of Science ®Google Scholar
• ShirasakaTShimamotoYFukushimaMInhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in ratsCancer Res19935317400440097689420
   PubMed Web of Science ®Google Scholar
• OhashiTOhnishiMTanahashiSMuraiMEfficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancerJpn J Clin Oncol201141334835221109512
   PubMed Web of Science ®Google Scholar
• LoehrerPJSrEinhornLHElsonPJA randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group studyJ Clin Oncol1992107106610731607913
   PubMed Web of Science ®Google Scholar
• von der MaaseHSengelovLRobertsJTLong-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancerJ Clin Oncol200523214602460816034041
   PubMed Web of Science ®Google Scholar
• PagliaroLCMillikanRETuSMCisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinomaJ Clin Oncol200220132965297012089226
   PubMed Web of Science ®Google Scholar
• ShinoharaNHarabayashiTSuzukiSSalvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapyCancer Chemother Pharmacol200658340240716416335
   PubMed Web of Science ®Google Scholar
• FurukawaTKubotaTHoffmanRMClinical applications of the histoculture drug response assayClin Cancer Res1995133053119815986
   PubMed Web of Science ®Google Scholar
• KitamuraHTaguchiKKunishimaYPaclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC groupCancer Sci201110261171117521323791
   PubMed Web of Science ®Google Scholar
• KuritaHYamamotoENozakiSMulticenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinomaCancer Chemother Pharmacol201065350350819579024
   PubMed Web of Science ®Google Scholar